NDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
17
Data completeness
5/8 — Partial
Priority Review
OXBRYTA (voxelotor) by Pfizer is hemoglobin s polymerization inhibitors [moa]. Approved for sickle cell disease. First approved in 2021.
Drug data last refreshed Yesterday
Mechanism of Action
Hemoglobin S Polymerization Inhibitors
Pharmacologic Class:
Hemoglobin S Polymerization Inhibitor
Indications (1)
Clinical Trials (17)
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
Started Oct 2023
6 enrolled
Sickle Cell Disease
Voxelotor Brain Oxygenation and Neurocognitive Study
Started Aug 2023
0Sickle Cell Disease
Voxelotor CYP and Transporter Cocktail Interaction Study
Started Apr 2023
44 enrolled
Sickle Cell Disease
Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor
Started Mar 2023
30 enrolled
Sickle Cell Disease
Voxelotor Neurocognitive Function Study
Started Jun 2022
1 enrolled
Sickle Cell Disease
Worked on OXBRYTA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.